NE

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of NE

What is NE? (Alpha-Tocopherol)

Property Description
Active ingredient Alpha-Tocopherol (alpha-tocopherol)
Form Soft oral capsules, liquid drops
Pharmacological class Fat-Soluble Vitamin and Antioxidant
Common use Prevention and treatment of Vitamin E deficiency
Origin Natural (d-alpha) or Synthetic (dl-alpha)

What Type of Compound is NE? (Identity and Classification)

NE is the designated term for a preparation whose active ingredient is alpha-Tocopherol, the most biologically significant isomer of Vitamin E. This substance belongs to the high-level pharmacological class of fat-soluble vitamins and is fundamentally an essential nutrient that the human body must obtain externally. The role of alpha-tocopherol is clinically recognized, as it is the form preferentially managed by specialized transport proteins within the human body to fulfill essential nutritional roles.

The preparation is classified as a nutritional agent and is often positioned as an Over-the-Counter (OTC) supplement, allowing patients to easily manage their dietary intake. Its classification as fat-soluble distinguishes it, requiring the presence of dietary fat for optimal assimilation.


Is Alpha-Tocopherol Natural or Synthetic? (Origin and Composition)

Alpha-Tocopherol can be sourced as Natural (d-alpha-tocopherol) from vegetable oils or produced Synthetically (dl-alpha-tocopherol). Pharmacological studies confirm that the natural form typically exhibits superior biological activity. Due to its inherent instability when exposed to air, the compound is often stabilized as an ester, such as alpha-tocopheryl acetate, which improves the product's resistance to environmental factors.

The formulation is designed for the Oral route of administration, with common dosage form(s) including soft oral capsules and liquid drops. These forms are particularly advantageous for patient groups requiring flexible supplementation options.


What is the General Purpose of This Essential Nutrient? (Core Benefit)

The primary general purpose of NE is to address or prevent a state of Vitamin E deficiency by supplying this vital nutrient. Its core function is acting as a powerful antioxidant that protects the body's cells from damage. The peroxyl radical scavenger action neutralizes unstable molecules called free radicals, thereby providing essential cell protection and stabilizing sensitive tissues. This critical defense mechanism ensures the structural and functional capacity of cell membranes is maintained across various physiological systems.

What side effects are possible with NE?

Possible Side Effects and Safety Information for Norepinephrine (NE)

Safety information for Norepinephrine is primarily based on its potent effects as a vasoconstrictor and cardiac stimulant. This section summarizes officially documented risks and restrictions.

Documented Adverse Reactions

The most commonly documented adverse reactions are hypertension (high blood pressure) and bradycardia (slowed heart rate).

Other adverse reactions that may occur include anxiety, transient headache, and respiratory difficulty.

System-Organ Class Common/Known Adverse Reactions
Cardiovascular Hypertension, Bradycardia, Cardiac Arrhythmias, Ischemic Injury
Nervous System Anxiety, Headache
Vascular/Local Extravasation Necrosis, Ischemia

Serious and Clinically Significant Risks

Administration carries several serious risks, predominantly related to its potent vasoconstrictive action:

  • Tissue Ischemia: The powerful constriction of blood vessels can lead to tissue ischemia (reduced blood supply), which may progress to gangrene of the extremities, especially following prolonged or high-dose infusions, or in patients with pre-existing vascular disease.
  • Extravasation Necrosis: Leakage of the medication outside of the vein (extravasation) can cause local tissue death (necrosis) and sloughing at the injection site. For this reason, continuous monitoring of the infusion site and infusion into a large vein are required.
  • Cardiac Arrhythmias: Norepinephrine can induce or exacerbate heart rhythm problems, particularly in the presence of hypoxia (low oxygen) or hypercarbia (high carbon dioxide).
  • Hypotension after Abrupt Discontinuation: A sudden cessation of the infusion can result in marked and dangerous hypotension (low blood pressure). The infusion rate must be reduced gradually upon discontinuation.

Safety Considerations and Restrictions

  • Pre-Existing Conditions: Use is generally avoided in patients with mesenteric or peripheral vascular thrombosis due to the increased risk of ischemia and infarction. Caution is also advised in patients with certain pre-existing heart rhythm issues or hypertension.
  • Volume Status: Official documentation states that hypovolemia (low blood volume) must be corrected before starting administration to prevent severe peripheral and visceral vasoconstriction, which can lead to tissue hypoxia and lactic acidosis.
  • Population-Specific Notes: The product may contain sodium metabisulfite, which can cause allergic reactions, including anaphylactic symptoms and asthma episodes, in susceptible individuals, particularly those with asthma.

High-Level Safety Summary

The overall safety profile is dominated by the need to meticulously manage the risk of severe cardiovascular and local tissue injury. Continuous monitoring of blood pressure, heart rate, and peripheral circulation is mandated to detect and rapidly manage complications such as severe hypertension, cardiac arrhythmias, and potential ischemic damage.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Alpha-Tocopherol (NE) overdose emphasizes the most significant potential complication: increased bleeding tendency (hemorrhage). This risk is particularly noted in patients with Vitamin K deficiency or those concurrently taking oral anticoagulant medications.

Overdose manifestations are primarily associated with chronic ingestion of high doses (exceeding 700 mg to 1,000 mg daily), and documented symptoms are often non-specific. These may include gastrointestinal disturbances such as diarrhea, nausea, abdominal cramps, along with systemic effects like headache, dizziness, fatigue, and weakness.

Official Emergency Actions

Situation Action Mandated by Regulators
Life-Threatening Symptoms Immediately call emergency services (911) if there is collapse, seizure, trouble breathing, or inability to be awakened.
Suspected Overdose Contact the Poison Control Helpline for guidance and consult a healthcare professional.

If overdose is suspected, the regulatory instruction is to stop the product immediately. General supportive measures should then be implemented. No specific antidote is known for Alpha-Tocopherol overdose. Monitoring of coagulation status, such as INR, may be required in high-risk individuals.

Therapeutic Uses of NE

What NE Treats: Main Uses and Benefits

The principal therapeutic role of Alpha-Tocopherol (NE) is the treatment and prevention of symptomatic Vitamin E deficiency, a condition arising from low levels of this essential fat-soluble nutrient. NE is commonly used when dietary intake is insufficient or when the body may not properly absorb the vitamin due to underlying health issues. This intervention contributes to improved comfort during periods of systemic imbalance by providing required nutritional support.


NE is primarily relevant for easing symptoms that cluster into neurological and motor impairments, such as challenges with coordination (ataxia), progressive muscle weakness, and specific sensory deficits. The therapy is applied in addressing these manifestations, which are consequences of chronic deficiency. The main conditions where this supportive management is commonly used include fat malabsorption disorders like Cystic Fibrosis and Crohn’s disease, and certain rare genetic conditions affecting nutrient transport.

“This intervention may assist with maintaining functional stability and supports the management of symptoms that create noticeable functional strain.”

The primary benefit is used for managing symptoms that create noticeable functional strain, thereby assisting with maintaining physical stability in vulnerable patient populations, including premature infants.


Quick Fact: Relief for Neurological and Motor Impairment

Supplementation helps address symptoms that interfere with daily comfort, focusing on preserving the integrity of nerve and muscle function during periods of chronic nutritional depletion.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Norepinephrine (NE) is used to raise blood pressure in adults with severe, acute hypotension. However, official regulatory documents restrict its use in several populations and medical circumstances.

Classification Who Should Not Use or Requires Caution
Contraindicated Patients under Cyclopropane or Halothane anesthesia due to risk of heart rhythm issues.
Restricted Use Patients with mesenteric or peripheral vascular thrombosis (blood clots), as it may worsen tissue damage, unless use is a life-saving measure.
Condition-Specific Patients who are hypotensive due to blood volume deficits (hypovolemia) must have the fluid imbalance corrected before or while NE is administered.
Drug Interactions Use with Monoamine Oxidase Inhibitors (MAOIs) or tricyclic antidepressants requires extreme caution due to the risk of severe, prolonged high blood pressure.
Age-Related Safety and effectiveness have not been established in pediatric patients. Caution is advised in elderly patients, and infusion into the leg veins should be avoided due to the risk of compromised circulation.
Other Patients with a known hypersensitivity to sulfites should use caution, as some preparations contain sodium metabisulfite.

Use in pregnancy is generally reserved for situations where the life-saving benefit to the mother outweighs the potential, unknown risk to the fetus.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Alpha-Tocopherol (NE) identifies several categories of documented interactions, which are classified based on the resulting effect on the body's systems or the plasma concentration of the active substance.


Pharmacodynamic Interactions

Co-administration of Alpha-Tocopherol with oral anticoagulant medicines (such as Warfarin) is officially associated with an increased risk of bleeding or hemorrhage. This interaction is classified as pharmacodynamic reinforcement. Similarly, concomitant use with antiplatelet agents (such as Aspirin) may contribute to an additive risk of bleeding.

Exposure-Modifying Interactions

Medicines that interfere with fat absorption are documented to reduce the exposure to Alpha-Tocopherol. Fat-absorption blocking medicines (e.g., Orlistat, Mineral Oil, Cholestyramine) are associated with reduced plasma concentrations of Alpha-Tocopherol due to interference with its gastrointestinal uptake. This interaction is pharmacokinetic in nature.

Supplement Interaction

High-dose Alpha-Tocopherol is stated in regulatory documents to antagonize the effects of Vitamin K supplements, which may be relevant in clinical settings where Vitamin K status is closely monitored. No mandatory timing or separation rules are explicitly documented in official labeling.

Mechanism of Action

The mechanism of Alpha-Tocopherol (NE) involves a primary antioxidant action coupled with distinct, non-antioxidant signaling roles, both of which engage in specific chemical reactions and signaling modulations at the cellular level.

️ Molecular Mechanism: Lipid Antioxidant and Membrane Protection

Alpha-Tocopherol acts as a peroxyl radical scavenger embedded in the lipid bilayers of cell membranes. By donating a hydrogen atom, it chemically terminates the chain reaction of lipid peroxidation, preventing the degradation of Polyunsaturated Fatty Acids (PUFAs). This action promotes the preservation of cell membrane structural integrity in tissues susceptible to oxidative stress, such as neuromuscular cells and erythrocytes.

Regulatory Mechanism: Signaling Pathway Modulation

Independent of its radical-scavenging properties, the molecule exerts regulatory control by modulating key intracellular pathways. It inhibits Protein Kinase C (PKC) activity and modulates gene expression for specific molecules, including those involved in cell adhesion and proliferation. This targeted mechanism reduces the expression of adhesion molecules on the vascular endothelium and limits excessive platelet aggregation, contributing to the modulation of vascular function.

Isomer Specificity and Sustained Physiological Presence

The biological activity of alpha-Tocopherol is influenced by its selective retention in the body, mediated by the hepatic Tocopherol Transfer Protein (alpha-TTP). This protein selectively binds the alpha isomer, ensuring it is preferentially maintained in plasma for systemic distribution. This unique, protein-mediated transport mechanism facilitates the selective retention and sustained concentration required for engaging both the chemical antioxidant and regulatory signaling mechanisms.

Dosage and Administration Information

How to Use Alpha-Tocopherol (NE)

Alpha-Tocopherol (NE) is primarily administered via the oral route using available dosage forms such as soft capsules, chewable tablets, or liquid drops. The medicine is designated for therapeutic use as an essential nutrient. Oral administration is strictly conditioned by the presence of dietary fat; consequently, the medicine must be taken with or immediately following a meal to ensure proper absorption.

Official dosing for the treatment of established deficiency is highly specific and depends on the underlying cause. Standard regimens for adult malabsorption disorders often fall within the range of 100 mg to 200 mg per day. For more severe conditions, such as Ataxia with Vitamin E Deficiency (AVED), the dose is significantly higher, typically 560 mg to 800 IU daily, which is usually administered as divided doses taken twice per day.

Age-specific dosing is utilized for pediatric patients and is determined by body weight or age. For instance, children under one year of age with malabsorption may receive 50 mg per day, with dosages increasing in older children. In cases of severe chronic malabsorption, such as cholestasis in infants, a specialized water-soluble form of the vitamin may be required for effective nutrient assimilation. Treatment is often long-term, and the effectiveness of the maintenance regimen is monitored through regular blood plasma testing to ensure therapeutic levels are maintained above a specified alpha-tocopherol:cholesterol ratio.

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Research Scope and Early Trials

Studies have explored whether the compound may impact inflammation in affected joints. Research into the compound's behavior focused on its action as a Janus kinase (JAK) inhibitor. This area of research aims to understand how modulating these intracellular signaling pathways might relate to the immune response.

Early Phase 1 and Phase 2 research was conducted to determine initial safety profiles and to explore dose-ranging effects in small cohorts of healthy volunteers and participants with Rheumatoid Arthritis (RA).


Key Findings from Clinical Trials (Phase 3)

Large-scale Phase 3 trials have investigated the use of the compound in adults with moderate to severe RA who had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

Joint Function and Disease Activity

Research has examined measures of joint function and mobility, such as the ACR scores (American College of Rheumatology response criteria), in participants with moderate to severe RA. Trial results reported the proportion of participants achieving ACR20, ACR50, and ACR70 responses at week 12 and week 24.

A Phase 3 trial reported findings related to changes in pain scores over a 52-week period. This trial used standardized pain assessment tools, such as the Visual Analog Scale (VAS), to quantify participant-reported changes.

Dosing and Regimen Studies

The trials examined various dosing regimens, including an initial lower dose, to collect data on measured effects and observed adverse events. A randomized controlled trial investigated a once-daily dosing schedule. Studies evaluated the effects of the compound when administered alone (monotherapy) and in combination with Methotrexate.


Evidence in Psoriatic Arthritis (PsA)

Research has also investigated the compound in patients with active Psoriatic Arthritis (PsA). Outcomes of interest included the ACR response rates and the Psoriasis Area and Severity Index (PASI) score for skin manifestations.

Frequently Asked Questions (FAQ)

Common questions about NE (FAQ)

Q: What is the safety classification of NE?

NE exists in different forms, which affects its classification. The nutritional form (Alpha-Tocopherol) is commonly described as a fat-soluble vitamin or nutritional supplement. However, the high-potency prescription form (Norepinephrine) is listed as a vasopressor and is subject to rigorous, controlled distribution.


Q: Is NE considered a strong or potent medicine?

Official regulatory documents describe one form of NE (Norepinephrine) based on its potent effects as a vasoconstrictor and cardiac stimulant. This classification reflects its ability to cause specific, monitored changes in the body.


Q: Is NE commonly prescribed to children or teenagers?

Official information is mixed and depends on the form of the medicine. For the nutritional form (Alpha-Tocopherol), specific dosing regimens include age-specific dosing for pediatric patients. Conversely, for the critical care form (Norepinephrine), regulatory documents state that safety and effectiveness have not been fully established in pediatric patients.


Q: Why is NE only available by prescription from a doctor?

The reason depends on the specific form of the medicine. The nutritional form of NE (Alpha-Tocopherol) is often classified as an Over-the-Counter (OTC) supplement. However, the critical care form (Norepinephrine) is restricted to prescription use because of its severe risks, and its classification as a pressor reflects its ability to cause specific, monitored changes, which requires close supervision.


Q: Does taking NE require any changes to diet or physical activity?

For the nutritional form of NE (Alpha-Tocopherol), official documents state that the medicine must be taken with or immediately following a meal to ensure the body absorbs it properly. Official regulatory documents typically focus on administration conditions and do not generally detail specific requirements related to physical activity.


Q: Is there a specific time of day that is generally recommended for taking NE?

Regulatory information for the nutritional form of NE specifies that the medicine must be taken with food for proper absorption. This is the main timing requirement, but official labeling does not usually define a specific time of day, such as morning versus evening.


Q: Can I use herbal or vitamin supplements while I am taking NE?

Official labeling describes a potential interaction where high doses of the nutritional form of NE (Alpha-Tocopherol) may antagonize the effects of Vitamin K supplements. This highlights the importance of discussing all concurrent supplements with a healthcare professional.


Q: Does NE interact with common non-prescription pain relievers like ibuprofen or acetaminophen?

Official regulatory information describes an additive risk of bleeding when one form of NE is used at the same time as antiplatelet agents. This risk is due to the combined effect of the medicines on blood clotting.


Q: Are there official warnings about NE use during pregnancy or breastfeeding?

Official labeling for the prescription form of NE states that use in pregnancy is typically reserved for life-threatening situations where the benefit to the mother outweighs the potential, unknown fetal risk. Information on use during breastfeeding is generally restricted or not provided in the primary documents.


Q: Is it safe to drive a car or operate machinery while taking NE?

Official documents indicate that certain adverse reactions, such as dizziness, fatigue, or headache, have the potential to impair a person’s ability to drive a car or operate machinery. Regulatory guidance notes this potential for impairment.


Q: Is it normal for NE to be described with a Boxed Warning in official materials?

Regulatory labeling for certain prescription drugs will prominently feature a Boxed Warning (sometimes called a Black Triangle in other regions) if one is required by the agency. If present, this is a normal part of the official safety documentation and highlights important safety concerns.


Q: How should a person generally react if they notice a severe, unexpected side effect?

Regulatory documents contain instructions detailing which specific side effects are described as requiring immediate medical attention and provide general guidance on reporting adverse events to health authorities. These instructions emphasize rapid communication with a healthcare professional.


Q: Are the serious side effects of NE considered common or rare?

Official documents describe the frequency of adverse reactions using standard terms like 'common,' 'uncommon,' or 'rare.' These terms correspond to the percentage of patients in clinical trials who reported the serious effect, and are intended to provide context on likelihood.


Q: What is the difference between an allergic reaction and a common side effect of NE?

Regulatory documents list both general adverse reactions (side effects) and specific potential allergic reactions to components of the medicine, such as sodium metabisulfite. These two categories are listed separately because they involve different types of biological response.


Q: Why do patients sometimes feel tired or drowsy when first starting NE?

Official documents list specific Central Nervous System (CNS) adverse reactions that are associated with NE. These effects, such as dizziness, fatigue, or headache, are related to the feelings of tiredness or drowsiness that some patients may experience.


Q: Are there any specific lab tests that NE is known to affect the results of?

The official monitoring regimen for the nutritional form of NE (Alpha-Tocopherol) relies on specific blood plasma testing. This test measures the alpha-tocopherol:cholesterol ratio to ensure therapeutic levels are maintained.


Q: What are the general guidelines if a dose of NE is missed?

Official regulatory documents provide specific, non-directive instructions on how to proceed with therapy if a dose is missed. These instructions describe the need to consult a healthcare professional to determine the appropriate next step for therapy.


Q: What does official documentation say about the risk of overdose with NE?

Official labeling includes a dedicated section detailing the symptoms, management, and treatment of overdosage for NE. This section is provided to inform health professionals about the steps to take if excessive amounts are administered.


Q: What are the potential effects of consuming a small amount of alcohol while taking NE?

Regulatory information provides statements on the potential interaction or reinforcement of effects when NE is combined with alcohol. This information is typically used by healthcare professionals when counseling patients.


Q: What is the peak effect time of NE after taking it?

Regulatory sections on the medicine's pharmacokinetics typically list the Tmax (time to reach maximum concentration). This metric describes the timeframe in which the medicine's highest concentration is usually reached in the body.


Q: Is NE a new drug or has it been used for a long time?

Regulatory sources typically cite the date of drug discovery or approval which provides context on its history. This information confirms that one form of NE (Alpha-Tocopherol) is a long-established essential nutrient, while the other (Norepinephrine) is a long-used vasopressor.


Q: Is NE approved for use in countries outside of the United States?

The existence of official regulatory documents from agencies outside the US, such as the European Medicines Agency (EMA) and Health Canada, indirectly indicates that NE is approved in those specific jurisdictions.

How should NE be stored and disposed of?

How to Store and Dispose of NE: Official Requirements

Storage Conditions: NE must be stored at controlled room temperature, typically within the range of 20 C to 25 C. The official labeling prohibits freezing and may specify that the medicine must not be stored above a certain temperature (e.g., 30 C). The product must be kept in its original packaging to ensure protection from both light and moisture.

Stability and Handling: Any unused or expired portions of NE must be discarded after a specified time period following the first opening or reconstitution, as defined in the official documentation. It is mandatory to keep NE out of the sight and reach of children.

Disposal Rules: To prevent environmental contamination, unused or expired NE must not be flushed down the toilet or placed in household trash. Disposal must occur through an authorized drug take-back program or pharmacy collection site, following established governmental guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of NE found in:

A-Z Index: